Cargando…
Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap
Recent single institution clinical trial successes with anti-CD19 Chimeric Antigen Receptor (CAR) T cell therapy for B cell malignancies attracted significant attention from industry. Our center sought to rapidly and safely bring industry sponsored pivotal trials to our patients and to prepare for a...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514522/ https://www.ncbi.nlm.nih.gov/pubmed/28716155 http://dx.doi.org/10.1186/s40425-017-0265-y |